Currently, there are 149.43M common shares owned by the public and among those 142.00M shares have been available to trade.
The company’s stock has a 5-day price change of 18.91% and 53.53% over the past three months. XERS shares are trading 53.98% year to date (YTD), with the 12-month market performance up to 145.07% higher. It has a 12-month low price of $1.69 and touched a high of $5.07 over the same period. XERS has an average intraday trading volume of 2.09 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 25.42%, 38.95%, and 71.55% respectively.
Institutional ownership of Xeris Biopharma Holdings Inc (NASDAQ: XERS) shares accounts for 43.38% of the company’s 149.43M shares outstanding.
It has a market capitalization of $803.57M and a beta (3y monthly) value of 1.18. The earnings-per-share (ttm) stands at -$0.38. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.40% over the week and 6.80% over the month.
Earnings per share for the fiscal year are expected to increase by 83.57%, and 299.45% over the next financial year.
Looking at the support for the XERS, a number of firms have released research notes about the stock. Piper Sandler stated their Neutral rating for the stock in a research note on November 11, 2024, with the firm’s price target at $3. Oppenheimer coverage for the Xeris Biopharma Holdings Inc (XERS) stock in a research note released on March 28, 2024 offered a Outperform rating with a price target of $5. Craig Hallum was of a view on August 28, 2023 that the stock is Buy, while Jefferies gave the stock Buy rating on October 21, 2022, issuing a price target of $4. Craig Hallum on their part issued Buy rating on April 28, 2022.
